Denali Therapeutics (DNLI) Net Equity Issued and Repurchased (2017 - 2026)

Denali Therapeutics (DNLI) posted quarterly Net Equity Issued and Repurchased of $12.4 million for Q1 2026, up 102.48% quarter-over-quarter from -$499.3 million in Q4 2024.

Denali Therapeutics (DNLI) Net Equity Issued and Repurchased (2017 - 2026) Analysis & Trends

Denali Therapeutics (DNLI) has reported Net Equity Issued and Repurchased for 5 consecutive years, with $12.4 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $12.4 million; the TTM figure through Mar 2026 stood at $12.4 million (up 102.48% YoY), while the FY2022 annual figure was $296.2 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased climbed to $12.4 million in Q1 2026 per DNLI's latest filing, from -$499.3 million in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $499.3 million in Q1 2024 and bottomed at -$499.3 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 141.90 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Denali Therapeutics 3.90 Bn 3.90 Bn 3.51 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 12.37 Mn
Mar 31, 2026 12.37 Mn
Dec 31, 2024 -499.25 Mn
Dec 31, 2024 -499.25 Mn
Mar 31, 2024 499.25 Mn
Mar 31, 2024 499.25 Mn
Mar 31, 2020 193.95 Mn
Mar 31, 2020 193.95 Mn
Dec 31, 2018 -94.41 Mn
Dec 31, 2018 -94.41 Mn
Mar 31, 2018 94.41 Mn
Mar 31, 2018 94.41 Mn
Dec 31, 2017 29.97 Mn
Dec 31, 2017 29.97 Mn